EUVIMEDEUVIMED entdecken
Crossref

Drugging the ferroptotic landscape of Friedreich’s Ataxia: Current paradigms and future directions

Giovanni Cravin, Giorgio Cozza

Ferroptosis and Oxidative Stress · 2026

DOI: 10.70401/fos.2026.0032 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Ferroptosis and Oxidative Stress, 2026. Verfasst von Giovanni Cravin und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Friedreich’s ataxia (FRDA) is a rare neurodegenerative condition driven by a severe deficiency of the mitochondrial protein frataxin (FXN). This depletion impairs mitochondrial iron-sulfur cluster biogenesis and disrupts intracellular iron homeostasis, ultimately promoting oxidative stress. Driven by localized iron overload and the continuous generation of reactive oxygen species, the resulting metabolic dysfunction renders vulnerable tissues highly susceptible to ferroptosis. This iron-dependent form of regulated cell death, executed through excessive lipid peroxidation, is now widely acknowledged as an important contributor to the neurodegeneration and hypertrophic cardiomyopathy that characterize FRDA. In the present review, we explore how FXN loss undermines cellular defenses against oxidative damage, placing a specific focus on the regulation of the lipid redox landscape. We detail the breakdown of glutathione (GSH)-dependent mechanisms, specifically highlighting the blunted Nrf2 antioxidant response and the subsequent reduced capacity of glutathione peroxidase 4. Alongside these deficits, we investigate the compensatory roles of GSH-independent rescue networks, namely ferroptosis suppressor protein 1 and mitochondrial dihydroorotate dehydrogenase. Looking toward clinical translation, we critically assess emerging pharmacological interventions designed to target these ferroptotic nodes. The potential of mitochondria-targeted iron chelators, lipoxygenase inhibitors, lipophilic radical-trapping antioxidants, and novel Nrf2 activators is evaluated to determine whether inhibiting ferroptosis can serve as a viable disease-modifying strategy. Moving forward, combinatorial “protect and restore” approaches will likely prove essential for maximizing therapeutic efficacy in FRDA.

Zitieren

APA

Cravin, G., & Cozza, G. (2026). Drugging the ferroptotic landscape of Friedreich’s Ataxia: Current paradigms and future directions. Ferroptosis and Oxidative Stress. https://doi.org/10.70401/fos.2026.0032

Vancouver

Cravin G, Cozza G. Drugging the ferroptotic landscape of Friedreich’s Ataxia: Current paradigms and future directions. Ferroptosis and Oxidative Stress. 2026. doi:10.70401/fos.2026.0032

BibTeX
@article{Cravin2026,
  author = {Cravin, Giovanni and Cozza, Giorgio},
  title = {Drugging the ferroptotic landscape of Friedreich’s Ataxia: Current paradigms and future directions},
  journal = {Ferroptosis and Oxidative Stress},
  year = {2026},
  doi = {10.70401/fos.2026.0032}
}
Kostenlos starten →